Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 9/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701833 | 0.91 | KCNQ3 (0.61) | KCNQ3KCNQ2NPC1RAB9AGAA | |
| SCHEMBL3702890 | 0.89 | KCNQ3 (0.62) | KCNQ3KCNQ2NPC1RAB9AGAA | |
| SCHEMBL3701258 | 0.82 | KCNQ3 (0.66) | KCNQ3KCNQ2MEN1ALPLPOLB | |
| SCHEMBL3713625 | 0.81 | KCNQ3 (0.64) | KCNQ3KCNQ2NPC1RAB9AGAA | |
| SCHEMBL3709168 | 0.76 | KCNQ3 (0.60) | KCNQ3KCNQ2NPC1RAB9AGAA | |
| SCHEMBL3701795 | 0.76 | KCNQ3 (0.61) | KCNQ3KCNQ2NPC1RAB9AGAA | |
| SCHEMBL3701681 | 0.75 | KCNQ3 (0.77) | KCNQ3KCNQ2NPC1 | |
| SCHEMBL3707988 | 0.74 | KCNQ3 (0.78) | KCNQ3KCNQ2 | |
| SCHEMBL3697377 | 0.72 | KCNQ3 (0.68) | KCNQ3KCNQ2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3707951 | 0.71 | KCNQ3 (0.67) | KCNQ3KCNQ2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KCNQ3 4/4885KCNQ2 2/4885NPC1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.